Sebastien Lefebvre's Recent LinkedIn Posts

What an amazing experience to take part in ring The Closing Bell® at the New York Stock Exchange (NYSE) on Tuesday, November 25, 2025, at 4:00 PM EST in honor of National Epilepsy Awareness Month! #NYSE #ClosingBell #NEAM2025 #AllInForEpilepsy

Proud of the team building the predictive design engine powering our seed design platform to tackle food insecurity, protect the planet and support farmer well-being. Check out our latest white paper, “The Promise of AI in Plant Breeding”

Exciting Partnership News 🤝 We're thrilled to announce that Prudentia is joining California Life Sciences (CLS) as a member and forming a strategic partnership to amplify our collective impact across California's biotech ecosystem. Why This Matters Now At a time when supporting US-based biotech innovation is more critical than ever, we're doubling down on our commitment to the emerging companies developing life-changing therapies for patients in need. This partnership represents a shared belief: breakthrough science deserves the resources and support to reach the patients who need it most. Our Shared Mission California Life Sciences has built an impressive network driving meaningful impact across the biotech community. We're honored to join forces with an organization that shares our dedication to accelerating innovation and supporting the next generation of therapeutic development. Through this partnership, Prudentia will engage with emerging biotechs to: -Rapidly assess their scientific approach and commercial potential -Strengthen their positioning for investment opportunities -Strategically stage their assets as they scale What's Next Together, we're creating pathways for innovative biotechs to move faster, smarter, and with greater confidence, ultimately getting transformative therapies to patients who are waiting. We couldn't be more excited about this collaboration and the doors it will open for the biotech innovators we're privileged to support. #CaliforniaLifeSciences #BiotechEcosystem #Drugdevelopment #Lifesciences #PatientsFirst #PrudentiaSciences

Excited to share this milestone for Prudentia Sciences. We hear every day from biopharma and investment teams that diligence is slow at exactly the moment when speed and confidence matter most. Proud to work with customers who are rethinking how deals get done, and to be part of a team building the infrastructure to support that shift. #LifeSciences #AI #Innovation #Dealmaking

When you join EmpowER&D, you become part of a revolutionary platform for turning epilepsy data into better care. You help build a future where epilepsy care is shaped by real people and real experiences. Every data point adds to your personalized dashboard of research on treatment options relevant to your care, as well as funding the collective mission of the Epilepsy Foundation. Your data is currency being reinvested directly into research and future programs for people affected by epilepsy. This only works if you show up. Join today: https://lnkd.in/eae7azJz

Your experience has power. By joining empowER&D™ and securely connecting your medical records, you’re helping turn lived experience into meaningful progress for the epilepsy community. As a thank you, the first 100 individuals who sign up and securely connect their medical records will receive a $20 gift card. The real impact is the role you play in advancing understanding, research, and hope so no one faces epilepsy alone. Sign up at https://bit.ly/empowERD5

We're heading to JPM Healthcare Conference next month and are excited to share how we're changing the deal-making landscape. Our AI-powered operating system is fundamentally changing how deals are being evaluated through: ✅ Seamless data connectivity ✅ Expert-driven scientific frameworks ✅ Comprehensive asset assessments The result? Diligence that used to take Months --> happening in Days. If you're evaluating external innovation at any stage, or actively searching for partners for your emerging assets, let's connect. Drop us a note below or DM us to schedule time. #JPM2026 #LifeSciences #LifeSciencesAI #DealMaking

Join us on Wednesday, October 1, at 6 PM to learn about an opportunity to get involved in beta testing the Epilepsy Foundation’s new centralized platform designed to drive progress and improve epilepsy treatment and outcomes. Register now: https://lnkd.in/eS8nuzxx

Living with epilepsy? Help shape the future of epilepsy research. We're inviting people living with epilepsy to test our new platform that connects real-world data from our epilepsy community, providers, and researchers. Your opinion matters. Join us Thursday, October 9, at 12 PM ET to learn more. https://lnkd.in/evgVS5HV

New EmpowER&D™ data shows how epilepsy and seizures shape daily life for the people who are participating. Half of the respondents shared that seizures or treatment affect many of the things they want to do. Another 31 percent said epilepsy influences almost everything in their life. Every experience matters, and every data point helps us understand what support, research, and resources are needed most. When you join EmpowER&D™, your story becomes part of the movement to improve life for everyone affected by epilepsy. Sign up today and use your data to power the next breakthrough: https://lnkd.in/eHEJpgcd

EmpowER&D is a revolutionary platform for turning epilepsy data into better care. If you have ever felt like your care decisions were out of your hands, this is a new path forward. The personalized dashboard gives you the ability to take action with your data. You decide what to share, how it is used, and why it matters. Every choice belongs to you. This is your story. This is your system now. Sign up at epilepsy.com/empowERD

Prism is helping pharma, biotech, and investors cut through data room complexity with speed and clarity. By synthesizing diligence data into a structured assessment framework, Prism benchmarks assets against public and proprietary intelligence, surfacing both risks and value drivers. The result: sharper insights and more confident decisions. Discover how Prism streamlines diligence 👉 https://lnkd.in/d6cRck5Z #PharmaInnovation #BiotechInvesting #DrugDevelopment #DueDiligence #LifeSciences #AssetValuation #SmarterDealmaking #AIDrivenInsights

🚀 Prudentia Sciences is heading to LSX USA Congress in Boston (September 16-17)! Excited to showcase how Prudentia Sciences' AI-powered platform is transforming life sciences investment decision-making. We accelerate due diligence, optimize portfolio management, and provide advanced valuation/risk simulation for breakthrough therapies. Perfect for: ✅ Biopharma BD&L teams managing deal flow and due diligence ✅ Life sciences investors enhancing portfolio strategy with AI analytics ✅ Biotech executives positioning asset value during dealmaking Attending? Let's meet and explore how AI can transform your investment workflow and maximize ROI while achieving greater patient impact. Schedule time with us here - https://bit.ly/4lZzjZt #LSXUSACongress #LifeSciences #AIinPharma #PrudentiaSciences

We are getting closer to a “working” quantum computer. Easy read on the challenges quantum computing faces. “For years, most quantum computers could only run for milliseconds, and even advanced machines that could run longer would operate for just around 13 seconds. But the Harvard team was able to run their system for more than two hours last month — and several of the researchers said the machine could, in theory, run indefinitely.” #QuantumComputing #Decoherence #ExponentialComputing #FutureOfComputing #DeepTech #NextGenInfrastructure #QuantumAI #AdvancedComputing

Very insightsful! Sounds counter intuitive given all the disruptions going on with generative AI and robotics. If you look at what is being produced nowadays…we are all racing to be the first to produce more of the same thing just using the latest tech.

We expected this and now it is happening. Good write up by Pradeep. “The Claude marketplace isn’t a product directory. It is a procurement layer” If this business model scales (ie more enterprise products join), it will allow companies to implement a faster “GenAI” transition instead of a piece meal transition. The enterprise workflows will need adjustments, enterprise data management and IT security will be in high demand!

Cassie Kozyrkov clearly sums up the challenge! #AIInfrastructure #AIChallenge

Worth watching to understand how newborn sequencing and whole genome sequencing at any point in your life can change your child or your own diagnostic journey. Early detection saves lives!